The market of tamsulosin, the original prostate drug, is maturing day by day

With the continuous investment in drug research and development of major pharmaceutical companies around the world, new drugs for the treatment of BPH are constantly supplementing the market Although there are many kinds of therapeutic drugs, α 1-adrenergic receptor inhibitors, 5 α - reductase inhibitors, androgen receptor antagonists and plant drugs dominate the medical market Stable growth is the main factor in the market of more than 50 drugs for the treatment of BPH Among them, α 1-adrenergic receptor inhibitors tansorosin, terazosin, avzosin and doxazosin are in the forefront 5 α - reductase inhibitors and androgen receptor antagonists finasteride, elistrazine and dutasteride together occupy the main market Although there are many kinds of plant drugs, and the side effects are small, but compared with the chemical drugs, they only occupy about 20% of the share   According to a recent foreign pharmaceutical market research report, the global sales volume of prescription drugs for BPH has been fluctuating between 4 billion and 5 billion US dollars In 2006, six of the top 500 drugs in the world were BPH drugs, with a total market volume of 4.291 billion US dollars, an increase of 5.02% compared with the previous year Affected by the product sales, only an increase was made in 2007 As long as US $4.306 billion, α 1-adrenergic receptor inhibitors account for three quarters of the market, of which tamsulosin has occupied half of the market for anti BPH   According to the data provided by the information center of the State Food and Drug Administration (SFDA), in 2007, the urinary system drug use in 16 sample hospitals in China was 494 million yuan, an increase of 17.87% over the previous year, of which the prostate drug use accounted for about half In 2007, the number of anti anterior adenoproliferative drugs increased by 10.71% over the previous year, and the drug varieties showed a highly concentrated trend Among them, finasteride, tamsulosin, doxazosin, propranolol, terazosin and epriete were the top six varieties in the sales amount of the sample hospitals, accounting for more than 90% of the prostate drug use, of which finasteride was the top one, accounting for 42%, while tamsulosin, the third generation long-acting α 1-adrenergic inhibitor, was the second, accounting for 21.73% It is estimated that the total amount of prostate drugs in China is about 2 billion yuan, with a slow overall growth Tamsulosin is the third generation of super selective long-acting α 1-adrenergic inhibitor, also known as tamoxin The drug was successfully developed by Yamauchi pharmaceutical company of Japan, and was approved by FDA for listing in July 1992 The product is named "Harnal" After the global business integration of Yamauchi pharmaceutical and Fujisawa pharmaceutical, they are now the products of Astaire After the listing of tamsulosin, bringer Ingelheim of Germany and Abbott of the United States jointly carried out the development of global market, which was approved by FDA of the United States in 1997 and listed under the trade name of "alna / Flomax" In 2003, the global sales volume of the three companies' products was US $2.64 billion, more than double that of the beginning of this century The sales volume of Zhongshan nei, bringer Ingelheim and Abbott were US $920, 996 and 724 million respectively With the promotion of products, tansorosin market is becoming mature In 2007, the sales volume of Flomax of bringer Ingelheim was US $1.281 billion, an increase of 10.62% over the previous year; the sales volume of Halle of Estella was US $1.126 billion, an increase of 3.78% over the previous year In the past four years, the average growth rate of tamsulosin is about 6% From the performance of two companies, i.e Boehringer Ingelheim and Abbott, we can see that the two varieties have shown wave like development, and after Zui, they have achieved stable growth in the global market In 2007, tamsulosin accounted for half of all anti BPH drugs Tansorosin is expected to continue to dominate in the next few years Tamsulosin is a high price drug in prostate drug market in China In 1996, tamsulosin sustained-release capsule in Shenyang shannei was put on the market separately in China, and obtained administrative protection in China Tamsulosin sustained-release capsule developed rapidly in similar products, its competitive momentum was strong, its share in the domestic market was rising, and it has entered the national basic drug catalog In March 2004, the administrative protection period of Halle in China ended After that, domestic tamsulosin APIs and sustained-release capsules were approved for production In 2002, Zhejiang hailisheng Pharmaceutical Co., Ltd obtained the production approval document with the trade name of "qisuo" Subsequently, Jiangsu Hengrui Pharmaceutical Co., Ltd., Kunming Jida Pharmaceutical Co., Ltd., Zhejiang Kangenbei Pharmaceutical Co., Ltd and Shandong lunanbeite Pharmaceutical Co., Ltd produced APIs and sustained-release preparations In 2008, they issued the production approval for APIs of Cihang Pharmaceutical Co., Ltd in Wuyi, Hengshui, Hebei Province According to the statistical data of 16 sample hospitals in China, the amount of tamsulosin used in 2005 has reached 36.72 million yuan, with a year-on-year increase of 23.37% in 2006 In 2007, the state adjusted the price of tamsulosin, which slowed down the increase of drug consumption The amount of drug use only increased by 6% compared with the previous year, but it still ranks the second place of anti prostate hyperplasia drugs The sales amount reached 48 million yuan, accounting for more than 20% of the total   According to the statistics of China Pharmaceutical Business Association, the wholesale market of tamsulosin has exceeded 100 million yuan According to the proportion of tamsulosin in the domestic market in recent years, the share of domestic drugs is growing year by year, which forces the share of imported drugs to decline The share of Halle has declined from 95% in 2005 to 92% in 2006 and 90% in 2007 The statistics of the first quarter of this year show that Music accounted for 88% Among the domestic drugs, Zhejiang hailisheng's "qisuo", Yunnan Kunming Jida pharmaceutical's "jidabente", Hangzhou Kangenbei's "Bitan" and Jiangsu Hengrui's tansoroxin accounted for 12% of the shares The market share of domestic tamsulosin sustained-release preparations increased steadily due to the same quality, efficacy and relatively low price The incidence rate of male prostatitis and benign prostatic hyperplasia is higher In recent years, the incidence of prostate disease in China has increased year by year At present, there are 30 million patients with BPH in the urban population, which is a very large market for elderly men's medicine With the improvement of medical level and the development of new drugs, the market of BPH drugs is still expanding Link prostate hyperplasia fast report (reporter Chen Guodong) recently held the fourth benign prostatic hyperplasia health education activities, the Chinese Medical Association experts pointed out that the incidence rate of benign prostatic hyperplasia has increased year by year, has become the main disease affecting the health of the elderly In order to improve the health care awareness of the elderly men and improve the quality of life of the elderly, we should publicize, promote and popularize the knowledge of BPH to the whole society The urology branch of Chinese Medical Association has long-term cooperation with anstelai company to hold large-scale health education activities for benign prostatic hyperplasia in 17 cities every year The activities will be carried out by urologists in the areas designated by the urological societies of different regions to teach the elderly men about BPH Benign prostatic hyperplasia (BPH) is a common disease of middle-aged and old men About half of men over 50 years old will have clinical symptoms With the increase of age, the incidence rate gradually increased At age 60~79, the incidence rate was more than 60%; men over 80 had a 80% chance of developing the disease The prostatic gland of hyperplasia squeezes urethra, causing a series of dysuria symptoms, such as frequent urination, weak urination, endless urination and so on These symptoms seriously affect the quality of life of patients If not treated in time, it will lead to many serious complications and even endanger the life of patients